Published in PLoS One on April 06, 2012
In vitro activity of rifampicin and verapamil combination in multidrug-resistant mycobacterium tuberculosis. PLoS One (2015) 1.39
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med (2013) 1.23
Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol (2014) 1.17
Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother (2014) 1.13
Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.12
Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2014) 0.99
Biological variability and the emergence of multidrug-resistant tuberculosis. Nat Genet (2013) 0.97
Performance of the GenoType MTBDRplus assay directly on sputum specimens from Brazilian patients with tuberculosis treatment failure or relapse. J Clin Microbiol (2013) 0.96
Multidrug Efflux Pumps in Staphylococcus aureus: an Update. Open Microbiol J (2013) 0.95
Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis (2014) 0.94
Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy. Drugs (2014) 0.94
Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance. PLoS One (2013) 0.92
Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. Antimicrob Agents Chemother (2014) 0.87
Role of the Mmr efflux pump in drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 0.87
Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Front Pharmacol (2014) 0.86
The role of transport mechanisms in mycobacterium tuberculosis drug resistance and tolerance. Pharmaceuticals (Basel) (2012) 0.85
Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations. Curr Top Microbiol Immunol (2013) 0.83
Membrane transport systems and the biodegradation potential and pathogenicity of genus Rhodococcus. Front Physiol (2014) 0.81
Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Front Microbiol (2015) 0.80
New and alternative approaches to tackling antibiotic resistance. F1000Prime Rep (2013) 0.80
Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery. MBio (2017) 0.80
New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. Front Microbiol (2017) 0.79
Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient. Pharmaceuticals (Basel) (2012) 0.79
Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis. PLoS One (2016) 0.78
dfrA thyA Double Deletion in para-Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains. Antimicrob Agents Chemother (2016) 0.77
Resistance to Antimicrobials Mediated by Efflux Pumps in Staphylococcus aureus. Antibiotics (Basel) (2013) 0.75
Impact of efflux in the development of multidrug resistance phenotypes in Staphylococcus aureus. BMC Microbiol (2015) 0.75
Discordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence Country. PLoS One (2016) 0.75
Role of Phenothiazines and Structurally Similar Compounds of Plant Origin in the Fight against Infections by Drug Resistant Bacteria. Antibiotics (Basel) (2013) 0.75
Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors. PLoS Negl Trop Dis (2017) 0.75
Antimycobacterial activity of five efflux pump inhibitors against Mycobacterium tuberculosis clinical isolates. J Antibiot (Tokyo) (2015) 0.75
Prevalence of mutations conferring resistance among multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in China. J Antibiot (Tokyo) (2015) 0.75
Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action. Antibiotics (Basel) (2017) 0.75
Triclosan-induced genes Rv1686c-Rv1687c and Rv3161c are not involved in triclosan resistance in Mycobacterium tuberculosis. Sci Rep (2016) 0.75
Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. BMC Infect Dis (2016) 0.75
Efflux attenuates the anti-bacterial activity of Q203 in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis. Front Microbiol (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet (1993) 16.75
Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol (2006) 12.53
The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature (1992) 11.99
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 11.22
Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature (1999) 6.91
Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A (1999) 4.33
Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol (1995) 3.98
Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother (2000) 3.27
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2006) 2.69
A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. Proc Natl Acad Sci U S A (2003) 2.50
The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol (2007) 2.27
The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res (2001) 2.25
The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother (2003) 2.12
Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol (2009) 1.98
The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect (2011) 1.97
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med (2011) 1.87
A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother (2009) 1.74
The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol Med (2002) 1.58
Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis (2010) 1.52
Antibiotic stress, genetic response and altered permeability of E. coli. PLoS One (2007) 1.50
Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother (2007) 1.48
Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother (2010) 1.47
Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob Agents Chemother (2001) 1.44
Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol (2006) 1.36
Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist (2010) 1.35
Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis (2008) 1.33
Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 1.30
Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother (2009) 1.29
Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol (2011) 1.28
mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob Agents Chemother (2005) 1.23
Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol (2011) 1.22
Mycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family. Clin Diagn Lab Immunol (1997) 1.19
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol (2011) 1.15
Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J Biol Eng (2009) 1.05
Role of P27 -P55 operon from Mycobacterium tuberculosis in the resistance to toxic compounds. BMC Infect Dis (2011) 1.04
Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol (2011) 1.04
Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health (2011) 1.03
Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother (2008) 0.98
Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist (2008) 0.96
The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int J Antimicrob Agents (2009) 0.96
jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol. Indian J Med Res (2010) 0.94
Mycobacterial efflux pumps and chemotherapeutic implications. Int J Antimicrob Agents (2003) 0.94
Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. Methods Mol Biol (2010) 0.94
An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. Int J Antimicrob Agents (2009) 0.81
Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors. Recent Pat Antiinfect Drug Discov (2011) 0.81
Noble metal nanoparticles applications in cancer. J Drug Deliv (2011) 1.66
Antibiotic stress, genetic response and altered permeability of E. coli. PLoS One (2007) 1.50
Increased Interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infect Dis (2004) 1.45
Noble metal nanoparticles for biosensing applications. Sensors (Basel) (2012) 1.44
Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta (2008) 1.40
Regenerative medicine as applied to solid organ transplantation: current status and future challenges. Transpl Int (2010) 1.33
Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. Antimicrob Agents Chemother (2005) 1.31
Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 1.30
Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2003) 1.30
Molecular characterization of methicillin-resistant Staphylococcus epidermidis clones: evidence of geographic dissemination. J Clin Microbiol (2002) 1.26
Geraniol restores antibiotic activities against multidrug-resistant isolates from gram-negative species. Antimicrob Agents Chemother (2009) 1.26
Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol (2011) 1.22
Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother (2007) 1.19
Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. Int J Antimicrob Agents (2008) 1.07
Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. BMC Microbiol (2011) 1.06
Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J Biol Eng (2009) 1.05
Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents (2008) 1.04
Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol (2011) 1.04
Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. J Antimicrob Chemother (2008) 1.04
Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother (2009) 1.01
High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother (2013) 1.00
Characterization of antimicrobial resistance in Salmonella enterica food and animal isolates from Colombia: identification of a qnrB19-mediated quinolone resistance marker in two novel serovars. FEMS Microbiol Lett (2010) 1.00
The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One (2010) 0.99
The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo (2007) 0.98
Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother (2008) 0.98
Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. Int J Antimicrob Agents (2002) 0.97
Gold on paper-paper platform for Au-nanoprobe TB detection. Lab Chip (2012) 0.97
Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist (2008) 0.96
The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int J Antimicrob Agents (2009) 0.96
Liver bioengineering: current status and future perspectives. World J Gastroenterol (2012) 0.95
Multidrug Efflux Pumps in Staphylococcus aureus: an Update. Open Microbiol J (2013) 0.95
An instrument-free method for the demonstration of efflux pump activity of bacteria. In Vivo (2006) 0.94
Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. Methods Mol Biol (2010) 0.94
Genetic characterisation of the ethambutol resistance-determining region in Mycobacterium tuberculosis: prevalence and significance of embB306 mutations. Int J Antimicrob Agents (2008) 0.94
Antimicrobial activity of phenothiazines. In Vivo (2005) 0.94
Mycobacterial efflux pumps and chemotherapeutic implications. Int J Antimicrob Agents (2003) 0.94
Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int J Antimicrob Agents (2007) 0.93
Inhibition of quorum-sensing signals by essential oils. Phytother Res (2010) 0.93
Au-nanoprobes for detection of SNPs associated with antibiotic resistance in Mycobacterium tuberculosis. Nanotechnology (2010) 0.92
The vitamin B1 metabolism of Staphylococcus aureus is controlled at enzymatic and transcriptional levels. PLoS One (2009) 0.92
Review. Comparison of multidrug resistant efflux pumps of cancer and bacterial cells with respect to the same inhibitory agents. In Vivo (2007) 0.92
Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev Anti Infect Ther (2012) 0.91
The mechanism of plasmid curing in bacteria. Curr Drug Targets (2006) 0.91
Identification of efflux pump-mediated multidrug-resistant bacteria by the ethidium bromide-agar cartwheel method. In Vivo (2011) 0.91
Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In Vivo (2010) 0.91
Biological activity of twenty-three hydantoin derivatives on intrinsic efflux pump system of Salmonella enterica serovar Enteritidis NCTC 13349. In Vivo (2011) 0.91
The phenothiazinium chromophore and the evolution of antimalarial drugs. Trop Med Int Health (2005) 0.89
In vitro activity of thioridazine against mycobacteria. Int J Antimicrob Agents (2009) 0.89
Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents (2012) 0.89
Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections. Expert Rev Anti Infect Ther (2010) 0.89
The added effect of thioridazine in the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis (2012) 0.88